Mircera The following types of<unk> s are available: * Erythropoietin (Epo) * Epoetin alfa (Procrit, Epogen) * Epoetin beta (NeoRecormon) * Epoetin zeta (Silapo, Retacrit) * Darbepoetin alfa (Aranesp) * Methoxy polyethylene glycol-epoetin beta (Mircera) Available forms Recombinant erythropoietin has a variety of glycosylation patterns giving rise to alpha, beta, delta, and omega forms: * epoetin alfa: * Darbepoetin (Aranesp) * Darbecept (Celon labs) * Epocept (Lupin pharma) * Nanokine (Nanogen Pharmaceutical biotechnology, Vietnam） * Epofit (Intas pharma) * Epogen, made by Amgen * Epogin * Eprex, made by Janssen-Cilag * Binocrit, made by Sandoz * PDpoetin, made by pooyeshdarou biopharmaceutical company IRAN * Procrit * Bioyetin, made by Probiomed * Abseamed (Medice Arzneimittel Pütter GmbH Co. KG) * epoetin beta: * NeoRecormon, made by Hoffmann–La Roche * Recormon * Methoxy polyethylene glycol-epoetin beta (Mircera) by Roche * epoetin delta: * Dynepo trademark name for an<unk><unk>  protein, by Shire plc * epoetin omega: * Epomax * epoetin zeta (biosimilar forms for epoetin alpha): * Silapo (STADA Arzneimittel AG) * Retacrit (Hospira, Pfizer Europe MA EEIG) * Miscellaneous: * Epocept, made by Lupin Pharmaceuticals * EPOTrust, made by Panacea Biotec Ltd * Erypro Safe, made by Biocon Ltd. * Repoitin, made by Serum Institute of India Limited * Vintor, made by Emcure Pharmaceuticals * Epofit, made by Intas pharma * Erykine, made by Intas Biopharmaceutica * Wepox, made by Wockhardt Biotech * Espogen, made by LG life sciences. * ReliPoietin, made by Reliance Life Sciences * Shanpoietin, made by Shantha Biotechnics Ltd * Zyrop, made by Cadila Healthcare Ltd. * EPIAO (rHuEPO), made by Shenyang Sunshine Pharmaceutical Co.. LTD. China * Cinnapoietin, made by CinnaGen biopharmaceutical Iran. Darbepoetin alfa, which early literature during its development often termed as novel<unk><unk>  protein (NESP), is a form created by five substitutions (Asn-30, Thr-32, Val-87, Asn-88 and Thr-90) that create two new N-glycosylation sites. This glycoprotein has a longer terminal half-life, meaning it is possible to administer it less frequently.
Erythropoiesis-stimulating agent
Immunosuppressive drug
Autotransfusionist
Iron preparation
Stem-cell therapy
Bisphosphonate
Thymus transplantation
Immunotherapy